Literature DB >> 31625523

Trastuzumab-conjugated nanoparticles composed of poly(butylene adipate-co-butylene terephthalate) prepared by electrospraying technique for targeted delivery of docetaxel.

Jaleh Varshosaz1, Erfaneh Ghassami2, Abdollah Noorbakhsh3, Mohsen Minaiyan4, Ali Jahanian-Najafabadi5.   

Abstract

Human epidermal growth factor receptor 2 (HER-2) is overexpressed in 20-30% of human breast cancers, associated with poor prognosis and tumour aggression. The aim of this study was the production of trastuzumab-targeted Ecoflex nanoparticles (NPs) loaded with docetaxel and in vitro evaluation of their cytotoxicity and cellular uptake. The NPs were manufactured by electrospraying and characterised regarding size, zeta potential, drug loading, and release behaviour. Then their cytotoxicity was evaluated by MTT assay against an HER-2-positive cell line, BT-474, and an HER-2-negative cell line, MDA-MB-468. The cellular uptake was studied by flow cytometry and fluorescent microscope. The particle size of NPs was in an appropriate range, with relatively high drug entrapment and acceptable release efficiency. The results showed no cytotoxicity for the polymer, but the significant increment of cytotoxicity was observed by treatment with docetaxel-loaded NPs in both HER-2-positive and HER-2-negative cell lines, in comparison with the free drug. The trastuzumab-targeted NPs also significantly enhanced cytotoxicity against BT-474 cells, compared with non-targeted NPs.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31625523      PMCID: PMC8676484          DOI: 10.1049/iet-nbt.2018.5363

Source DB:  PubMed          Journal:  IET Nanobiotechnol        ISSN: 1751-8741            Impact factor:   1.847


  19 in total

Review 1.  Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials.

Authors:  Irina Ghislain; Efstathios Zikos; Corneel Coens; Chantal Quinten; Vasiliki Balta; Konstantinos Tryfonidis; Martine Piccart; Dimitrios Zardavas; Eva Nagele; Vesna Bjelic-Radisic; Fatima Cardoso; Mirjam A G Sprangers; Galina Velikova; Andrew Bottomley
Journal:  Lancet Oncol       Date:  2016-07       Impact factor: 41.316

2.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

3.  Optimisation of processing variables effective on self-assembly of folate targeted Synpronic-based micelles for docetaxel delivery in melanoma cells.

Authors:  Somayeh Taymouri; Jaleh Varshosaz; Farshid Hassanzadeh; Shaghayegh Haghjooy Javanmard; Nasim Dana
Journal:  IET Nanobiotechnol       Date:  2015-10       Impact factor: 1.847

4.  AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery.

Authors:  Athulya Aravind; Prashanti Jeyamohan; Remya Nair; Srivani Veeranarayanan; Yutaka Nagaoka; Yasuhiko Yoshida; Toru Maekawa; D Sakthi Kumar
Journal:  Biotechnol Bioeng       Date:  2012-06-01       Impact factor: 4.530

Review 5.  Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.

Authors:  H Van Poppel
Journal:  Can J Urol       Date:  2005-02       Impact factor: 1.344

6.  Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.

Authors:  Hyun-Soo Cho; Karen Mason; Kasra X Ramyar; Ann Marie Stanley; Sandra B Gabelli; Dan W Denney; Daniel J Leahy
Journal:  Nature       Date:  2003-02-13       Impact factor: 49.962

7.  Controlling coupling reaction of EDC and NHS for preparation of collagen gels using ethanol/water co-solvents.

Authors:  Kwangwoo Nam; Tsuyoshi Kimura; Akio Kishida
Journal:  Macromol Biosci       Date:  2008-01-09       Impact factor: 4.979

Review 8.  Docetaxel-related side effects and their management.

Authors:  Jackie Baker; Jaffer Ajani; Florian Scotté; Dorte Winther; Miguel Martin; Matti S Aapro; Gunter von Minckwitz
Journal:  Eur J Oncol Nurs       Date:  2008-05-22       Impact factor: 2.398

Review 9.  The changing global patterns of female breast cancer incidence and mortality.

Authors:  Freddie Bray; Peter McCarron; D Maxwell Parkin
Journal:  Breast Cancer Res       Date:  2004-08-26       Impact factor: 6.466

10.  Pharmacokinetics and in vitro/in vivo antitumor efficacy of aptamer-targeted Ecoflex® nanoparticles for docetaxel delivery in ovarian cancer.

Authors:  Erfaneh Ghassami; Jaleh Varshosaz; Ali Jahanian-Najafabadi; Mohsen Minaiyan; Parvin Rajabi; Effat Hayati
Journal:  Int J Nanomedicine       Date:  2018-01-23
View more
  1 in total

Review 1.  HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment.

Authors:  Leopoldo Sitia; Marta Sevieri; Lorena Signati; Arianna Bonizzi; Arianna Chesi; Francesco Mainini; Fabio Corsi; Serena Mazzucchelli
Journal:  Cancers (Basel)       Date:  2022-05-13       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.